ETELCALCETIDE – A STEP FORWARD IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/9ec1148cbdb3c5af52dc88c35e69bd8f.pdf
ETELCALCETIDE – A STEP FORWARD IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Snezana
Pesic
Snezana Pesic snezana.pesic74@gmail.com Zvezdara University Clinical Hospital Clinical Department of Nephrology Belgrade Serbia *
Radomir Naumovic radomirnaumovic450@gmail.com Zvezdara University Clinical Hospital, Faculty of Medicine, University of Belgrade Clinical Department of Nephrology Belgrade Serbia -
 
 
 
 
 
 
 
 
 
 
 
 
 

Secondary hyperparathyroidism (SHPT) is one of the major risk factors for cardiovascular disease (CVD) in hemodialysis patients. Effective SHPT treatment remains a crucial challenge in reducing morbidity and mortality of these patients. Beside of dietary measures, phosphate binders, and vitamin D₃ analogs, the introduction of calcimimetics has significantly transformed the therapeutic landscape, improving both biochemical control and patient adherence. This study aimed to evaluate the efficacy and safety of etelcalcetide in achieving and maintaining target levels of parathyroid hormone (PTH), calcium, and phosphate in chronic hemodialysis patients.

A prospective study followed 41 chronic hemodialysis patients with SHPT during five years period2021–2025). PTH, calcium, and phosphate levels were measured during etelcalcetide treatment, as well asand adverse events such as hypocalcemia or treatment interruption.

Forty-one patients (56.1% male, mean age 58.6 ± 12.6 years, mean dialysis vintage 109.6 ± 70.5 months) received etelcalcetide during 18.3 ± 12.7 months at 8.5 ± 3.7 mg three times weekly. Baseline PTH was 1094 ± 502 pg/mL, decreasing to 474.3 ± 331.9 pg/mL at the end of follow-up (t = 7.13; p < 0.001). The mean reduction was 50.4% (max > 94%). Asymptomatic hypocalcemia occurred in 5 patients and was managed conservatively. Oone patient required treatment discontinuation due to PTH less than 100 pg/mL.

Etelcalcetide therapy in hemodialysis patients provides a significant reduction in PTH and better SHPT control with excellent tolerability. These results confirm etelcalcetide as a meaningful step forward in the modern management of SHPT.

Kewords